TDC
VYGR icon

Thompson Davis & Co’s Voyager Therapeutics VYGR Stock Holding History

Thompson Davis & Co’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$217K Sell
11,451
-500
-4% -$9.59K 0.47% 53
2018
Q2 		$234K Buy
11,951
+7,800
+188% +$154K 0.56% 43
2018
Q1 		$78K Sell
4,151
-3,334
-45% -$72.1K 0.21% 115
2017
Q4 		$124K Buy
7,485
+3,021
+68% +$51.8K 0.29% 84
2017
Q3 		$92K Buy
+4,464
New +$50.4K 0.16% 140

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Thompson Davis & Co's VYGR Position: Q3 2018 in Review

Thompson Davis & Co reduced its Voyager Therapeutics (VYGR) stake by 4.2% in Q3 2018, selling an estimated $9.59K and leaving 11,451 shares worth $217K. The position accounts for 0.47% of the portfolio, ranked #53.

Thompson Davis & Co first reported a position in VYGR in Q3 2017 and has held it in 5 quarters since. The position peaked at $234K in Q2 2018. 119 funds tracked by Wall St. Rank hold VYGR as of Q3 2018.

  • Thompson Davis & Co held 11,451 shares of Voyager Therapeutics worth $217K as of Q3 2018.
  • Thompson Davis & Co sold 500 Voyager Therapeutics shares in Q3 2018, an estimated $9.59K.
  • Voyager Therapeutics made up 0.47% of Thompson Davis & Co's portfolio in Q3 2018, its #53 holding.
  • Thompson Davis & Co first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 5 quarters since.
  • Thompson Davis & Co's Voyager Therapeutics position peaked at $234K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.